HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned [1] [2] [3] . However, recently developed single-cell-based antibody cloning methods have uncovered a new generation of far more potent broadly neutralizing antibodies to HIV-1 (refs 4, 5) . These antibodies can prevent infection and suppress viraemia in humanized mice and nonhuman primates, but their potential for human HIV-1 immunotherapy has not been evaluated [6] [7] [8] [9] [10] . Here we report the results of a firstin-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 binding site antibody 11 , in uninfected and HIV-1-infected individuals. 3BNC117 infusion was well tolerated and demonstrated favourable pharmacokinetics. A single 30 mg kg 21 infusion of 3BNC117 reduced the viral load in HIV-1-infected individuals by 0.8-2.5 log 10 and viraemia remained significantly reduced for 28 days. Emergence of resistant viral strains was variable, with some individuals remaining sensitive to 3BNC117 for a period of 28 days. We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure.
A fraction of HIV-1-infected individuals develop potent neutralizing serologic activity against diverse viral isolates 4, 5 . Single-cell cloning methods to isolate antibodies from these individuals 12 revealed that broad and potent neutralization can be achieved by antibodies targeting many sites on the viral envelope 5, 13, 14 . Many of these antibodies can prevent infection, and some can suppress active infection in humanized mice (hu-mice) or macaques [6] [7] [8] [9] [10] . Therefore, it is generally accepted that a vaccine eliciting such antibodies is likely to be protective against HIV-1. However, potent anti-HIV-1 broadly neutralizing antibodies (bNAbs) are highly somatically mutated and many carry other uncommon features such as insertions, deletions, or long complementary determining regions 4, 5, 11, 12, 15 , which may account for the difficulty in eliciting such antibodies by immunization. In view of the efficacy of passive bNAb administration in hu-mice and macaques [6] [7] [8] [9] 16 , it has been suggested that bNAbs should be administered passively, or by viral vectors for prevention and immunotherapy 4, 9, 16 . However, their safety and efficacy has not been tested in humans.
To determine whether the new generation of more potent bNAbs are safe and active against HIV-1 in humans, we initiated an open label phase 1 study (Fig. 1a) with 3BNC117, an anti-CD4 binding site antibody cloned from a viraemic controller 11 . 3BNC117 neutralizes 195 out of 237 HIV-1 strains comprising 6 different clades with an average half-maximal inhibitory concentration (IC 50 ) of 0.08 mg ml 21 (Extended Data Fig. 1 ) 11 . 12 uninfected and 17 HIV-1-infected individuals (Table 1) were administered a single intravenous dose of 1, 3, 10 or 30 mg kg 21 of 3BNC117 (Extended Data Table 1a ). 3BNC117 serum concentrations, plasma HIV-1 viral loads (VL), CD4
1 and CD8 1 T-cell counts, and safety were monitored closely ( Tables 1b, 2 ). The two groups were comparable for gender, race and age (Table 1) .
3BNC117 was generally safe and well tolerated at all doses tested in both uninfected and HIV-1-infected individuals. No grade 3, 4 or serious adverse events and no treatment-related laboratory changes were observed during 56 days of follow up (Extended Data Table 1b) . CD4
1 or CD8 1 T-cell counts did not change after 3BNC117 infusion in the HIV-1-infected group, possibly because initial CD4
1 T-cell counts were near normal in most participants (mean absolute CD4 Two different assays were used to measure 3BNC117 levels in serum: TZM.bl neutralization assay to measure activity, and anti-idiotype-specific ELISA to measure antibody protein levels (Fig. 1b , Extended Data Fig. 3 and Extended Data Tables 4, 5 ). With few exceptions the two assays were generally in agreement in both groups ( Fig. 1b and Extended Data Fig. 3 ). However, elimination of 3BNC117 activity was more rapid in the HIV-1-infected group, resulting in an estimated average t 1/2 of around 9 days as opposed to around 17 days in uninfected individuals ( Fig. 1b and Extended Data Tables 4, 5) . We conclude that 3BNC117 has pharmacokinetic properties consistent with a typical human IgG1 in uninfected individuals and a somewhat faster decay rate in HIV-1-viraemic individuals. Similar antigen-dependent enhanced clearance has been reported with anti-cancer antibodies 17 . Although there may be other explanations, we speculate that the increased rate of antibody elimination in the presence of HIV-1 is due to accelerated clearance of antigen-antibody complexes. Viral loads were measured by standard assays or by single-copy assays. Baseline VLs in HIV-1-infected individuals not on anti-retroviral therapy (ART) varied from 640 to 53,470 copies ml 21 (mean 9,420 copies ml
21
). Two participants were on ART at the time of antibody infusion but had detectable baseline VLs (30 and 100 copies ml
). (Table 1, Extended Data Table 2a) .
Virologic responses correlated with antibody dose. Infected individuals receiving 1 or 3 mg kg 21 3BNC117 doses showed only small and transient changes in viraemia consisting of increases of up to threefold 1 day after infusion, followed by a short temporary decrease, and rapid return to baseline (Fig. 2, Extended Data Fig. 4 , and Extended Data Table 2a ). The magnitude and kinetics of the initial increase in viraemia were consistent with those seen with viral entry inhibitors 18 . In contrast, 10 out of 11 individuals receiving 10 or 30 mg kg 21 infusions responded by dropping their VLs by up to 2.5 log 10 ( Fig. 2 , Extended Data Fig. 4 and Extended Data (Figs 2 and 3 and Extended Data Table 2a , b). The magnitude of the decline was related to the starting VL and the sensitivity of the subjects' autologous virus to 3BNC117 (Figs 2 and 3, Extended Data Fig. 5 ). The median time to reach the lowest level in viraemia was 7 days, and the mean drop in VL was 1.48 log 10 at lowest level. When compared to all available pre-treatment measurements, the drop in viraemia was highly significant from days 4 through 28 ( Fig. 2 and Extended Data Table 2b ). Although the limited data set does not allow us to determine viral set point, 4 of the 8 individuals receiving a single 30 mg kg 21 infusion did not entirely return to day 0 pre-infusion levels during the observation period of 56 days (Figs 2 and 3, Extended Data Table 2a ).
To further examine the virologic effects of 3BNC117 immunotherapy, autologous viral isolates were obtained from cultured PBMCs before (day 0, day 27) and after (day 28) antibody infusion. Paired samples from 12 of the 17 HIV-1-infected individuals were tested for 3BNC117 sensitivity ( Fig. 3 and Extended Data Table 3 ). Samples obtained from individuals infused with 1 mg kg 21 showed 35-and 13.5-fold decreases in 3BNC117 sensitivity, indicating that the antibody exerts selective pressure on HIV-1 even at the lowest dose (2A3, 2A4; Fig. 3 ). Similar changes in sensitivity were seen for some (2B1, 2C5) individuals treated with 3 and 10 mg kg 21 , but others remained 3BNC117-sensitive throughout (2B3) (Fig. 3 , Extended Data Table 3) . Similarly, at 30 mg kg 21 , only 2 out of 5 individuals tested showed greater than fivefold reduction in 3BNC117 sensitivity on day 28 (Extended Data Table 3 ). In contrast, 2C1, 2D1, 2D3 showed only 3.2-, 1.3-and 2.7-fold changes in sensitivity and these individuals did not rebound to baseline viraemia levels at day 28 (Figs 2 and 3) . We conclude that, in some individuals, HIV-1 develops high-level resistance to 3BNC117 by 28 days after a single dose, while in others it does not.
To examine the molecular nature of the changes in HIV-1 in response to 3BNC117, we cloned and sequenced HIV-1 envelopes from paired plasma samples from 10 individuals before and 28 days after infusion. Evidence for antibody-induced selection was seen in some but not all samples analysed (Fig. 4, Supplementary Fig. 1 ). For example, 2C5, who received a 10 mg kg 21 infusion, selected for a G459D mutation in 15 out of 23 env sequences, while the remainder showed a longer V5 loop. The G459D mutation alters the CD4 binding site and can result in resistance to 3BNC117 (ref. 9) . Changes in the V5 loop can alter sensitivity to anti-CD4 binding site antibodies by steric clashing with the heavy or light chains of 3BNC117-type antibodies. Similarly, 10 or 30 mg kg 21 infusions selected single mutations at Q363H (2E1), S461D (2E2), and S274Y (2E2) (Fig. 4, Supplementary Fig. 1 ). These changes may alter sensitivity to 3BNC117 by interfering with binding 5 . Selection in these 3 individuals is also indicated by the emergence of a distinct group of closely related sequences in phylogenetic trees (Fig. 4,  Supplementary Fig. 1 ). Consistent with the molecular analysis, and the viral culture data (Fig. 3) , pseudoviruses produced from serum of 2C5 from days 0 and 28 showed high level 3BNC117 resistance, whereas the changes in pseudoviruses produced from 2C1, 2D1, 2E1 and 2E2 were modest ( Fig. 4 and Extended Data Table 3 ). In contrast, autologous viral isolates from individuals who did not become resistant, or had only small changes in sensitivity, such as 2B3, showed little if any evidence of selection. We conclude that a single infusion of 3BNC117 leads to selection for high-level resistance in some but not all individuals.
Although immunotherapy was initially used to treat infectious diseases, the great majority of therapeutic monoclonal antibodies are currently used to treat cancer and autoimmune diseases. This form of therapy has been shown to be highly effective, well tolerated, and to function in large part by engaging the host immune system through Fc receptors 19 . In contrast, a role for antibodies in controlling HIV-1 infection has been difficult to establish. For example, the overall course of infection is 3BNC117 dose indicated in red. Plots (left column) show absolute VLs in HIV-1 RNA copies ml 21 (y axis) versus time in days after infusion (x axis). Right column shows log 10 changes in VL from day 0. Red line illustrates the average (least-squares means, by mixedeffect linear model). Individual subjects are indicated on the right. Subjects 2E1 to 2E5 were pre-screened for 3BNC117 sensitivity. At 30 mg kg 21 dose level, the change in viraemia was significant (P 5 0.004, P , 0.001, P , 0.001, P , 0.001, P , 0.011 at days 4, 7, 14, 21, and 28, respectively) when compared to all available pretreatment values (Extended Data Table 2b ). not thought to be altered in individuals that develop bNAbs 20 . Moreover, first generation anti-HIV-1 bNAbs with limited breadth and activity produced little if any measurable effects in hu-mice or viraemic individuals 3, 4, 21 . However, antibodies can put strong selective pressure on the virus in individuals that develop anti-HIV-1 antibody responses [22] [23] [24] . In addition, recent studies in hu-mice showed that, when administered as monotherapy, new generation bNAbs can transiently reduce VLs, and in combination they control viraemia for as long as concentrations remain in the therapeutic range 6, 9 . In contrast, single antibodies led to control of viraemia in SHIV-infected macaques for as long as antibody levels remained therapeutic, and immune escape was rarely observed 7, 8 . The surprising difference between hu-mice and macaques might be attributed in part to an intact host immune system in the macaque, including endogenous antibodies 25 , or differences between SHIV and HIV-1 infection. Our data establish that passive infusion of single bNAbs can have profound effects on HIV-1 viraemia in humans.
Combinations of antiretroviral drugs are the standard of care for HIV-1 infection because resistance develops to single agents 26 . Similarly, monotherapy with 3BNC117 alone is insufficient to control infection, and we expect that antibody-drug or antibody-antibody combinations will be required for complete viraemic control. Although the current generation of drugs is less expensive than antibodies, the latter have very long half-lives and have the potential to kill infected cells and to enhance host immunity by engaging Fc receptors 19, 27 . Moreover, anti-HIV-1 antibodies can be made 100-fold more potent by molecular engineering 28 . Finally, the combination of antibodies with agents that activate latent viruses can interfere with the HIV-1 reservoir in humice 29 and may be critical to HIV-1 eradication strategies. Given the difficulties in developing an HIV-1 vaccine and in eradicating established infection, passive transfer of monoclonal antibodies is being considered for HIV-1 prevention, therapy, and cure. Our data establish the principle that monoclonal antibodies can be both safe and effective against HIV-1 in humans. Antibody-mediated immunotherapy differs from currently available drugs in that it has the potential to affect the course of HIV-1 infection by engaging host immunity directly.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . All participants provided written informed consent before participation in the study and the study was conducted in accordance with Good Clinical Practice. The protocol was approved by the Federal Drug Administration in the USA, the Paul Ehrlich Institute in Germany and the Institutional Review Boards at the Rockefeller University and the University of Cologne. Study participants. All study participants were recruited at the Rockefeller University Hospital, New York, USA and at the University Hospital Cologne, Cologne, Germany. Eligible subjects were adults aged 18-65 years, HIV-1-infected or uninfected, and without concomitant hepatitis B or C infections. HIV-1-infected subjects enrolled in study groups 2A through 2E were ART-experienced or naive. In groups 2A through 2D, subjects were either off standard ART for at least 8 weeks before study participation and had plasma HIV-1 RNA levels between 2,000 and 100,000 copies ml 21 , or they were on standard ART but had plasma HIV-1 RNA levels .20 copies ml 21 , measured on two separate occasions at least 1 week apart. Subjects recruited into group 2E were HIV-1-infected, off ART (2,000-100,000 copies ml 21 ), and differed from the other groups in that they were pre-screened for sensitivity to 3BNC117 as described below. Subjects with CD4
1 T-cell counts ,300 cells ml
, clinically relevant deviations from normal physical findings, abnormal electrocardiogram (ECG), and/or laboratory examinations were excluded. Women of childbearing potential were required to have a negative result of a serum pregnancy test on the day of 3BNC117 infusion. HIV-1-infected individuals, who were not on standard ART at enrolment, were given the option to initiate ART 6 weeks after 3BNC117 infusion. Study procedures. The appropriate volume of 3BNC117 was calculated according to study dose group, diluted in sterile normal saline to a total volume of 100 or 250 ml, and administered intravenously over 60 min. Study participants received 3BNC117 on day 0 and remained under close monitoring in the inpatient unit of the Rockefeller University Hospital for 24 h. Participants returned for frequent follow up visits for safety assessments that included physical examination, measurement of clinical laboratory parameters such as haematology, chemistries, urinalysis, coagulation times, pregnancy tests (for women) as well as HIV-1 viral loads and CD4
1 and CD8 1 T-cell counts (Fig. 1a) . Adverse events were graded according to the DAIDS AE Grading Table ( HIV-1-infected groups) or the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (uninfected groups). Blood samples (30 to 120 ml) were collected before and at multiple times after 3BNC117 infusion. Samples were processed within 4 h of collection, and serum and plasma samples were stored at -80 uC. PBMCs were isolated by density gradient centrifugation. The absolute number of peripheral blood mononuclear cells was determined by an automated cell counter (Vi-Cell XR; Beckman Coulter), and cells were cryopreserved in fetal bovine serum plus 10% DMSO. Plasma HIV-1 RNA levels. Plasma was collected for measuring HIV-1 RNA levels at screening (from day -49 to day 214), the day -7 pre infusion visit (from day 242 to day 22), day 0 (before infusion), and on days 1, 4, 7, 14, 21, 28, 42 and 56. HIV-1 RNA levels were determined using the Roche COBAS AmpliPrep/ COBAS TaqMan HIV-1 Assay, Version 2.0, which detects 20 to 10 3 10 6 copies ml
, or by the ABBOTT RealTime Assay, which detects 40 to 10 3 10 6 copies ml 21 . In samples with HIV-1 RNA ,20 copies ml
, viraemia was measured by a quantitative real-time, reverse transcriptase (RT)-initiated PCR (RT-PCR) assay that can quantify HIV-1 RNA down to 1 copy ml 21 as previously described 31 .
CD4
1 and CD8 1 T cells. CD4 1 and CD8 1 T-cell counts were determined at screening, on day 0 (before infusion), and day 28 by a clinical flow cytometry assay, performed at LabCorp or at the University Hospital Cologne. Leukocytes were determined as CD45 1 cells. Percentage of cells positively stained for CD3, CD4, CD8 as well as the CD4/CD8 ratio were analysed with the BD Multiset software (BD Biosciences). 3BNC117 study drug. 3BNC117 is a recombinant, fully human IgG1k mAb recognizing the CD4 binding site on the HIV-1 envelope 11 . The antibody was cloned from an HIV-1-infected viraemic controller in the International HIV Controller Study 11, 32 , expressed in Chinese hamster ovary cells (clone 5D5-5C10), and purified using standard methods. The 3BNC117 drug substance was produced at Celldex Therapeutics Fall River (MA) GMP facility, and the drug product was fill-finished at Gallus BioPharmaceuticals (NJ). The resulting purified 3BNC117 was supplied as a single use sterile 20 mg ml 21 of an anti-idiotypic antibody specifically recognizing 3BNC117 (anti-ID 1F1 mAb), and incubated overnight at 2-8 uC. After washing, plates were blocked for 1 h with 5% BSA. Serum samples, QCs and standards were added (1:50 minimum dilution in 5% BSA) and incubated for 1 h at room temperature. 3BNC117 was detected using an horseradish peroxidase (HRP)-conjugated mouse antihuman IgG kappa-chain-specific antibody (Abcam PN: ab79115) and the HRP substrate tetra-methylbenzidine. 3BNC117 concentrations were then interpolated from a standard curve of 3BNC117 using a 4 parameter logistic curve-fitting algorithm. The reference standard and positive controls were created from the drug product lot of 3BNC117 used in the clinical study. The capture anti-idiotypic antibody was produced by immunizing BALB/c mice with a Fab9 fragment of 3BNC117 and plasma was tested for the presence of neutralizing antibodies in an ELISA. Briefly, the HIV-1 antigen (2CC core protein) was coated to a plate and blocked. Plasma dilutions were pre-incubated with a sub-saturating concentration of 3BNC117 then added to the plate. Binding to the antigen was detected with an HRP-conjugated goat anti-mouse IgG-Fc specific antibody. Plasma was considered neutralizing if it was able to block the binding of 3BNC117 to the antigen coated plate. Two mice were selected for fusion. Those hybridomas that showed high specificity when comparing binding to 3BNC117 versus binding to the irrelevant human IgG1 antibody were selected to expand, screened in the neutralization assay as described above, subcloned and purified for use in the anti-idiotypespecific ELISA.
In addition, the concentration of active 3BNC117 was determined by TZM.bl neutralization assay 7, 8 . Serum samples were heat-inactivated for 1 h at 56 uC and measured for neutralizing activity against an HIV-1 strain that was highly sensitive to 3BNC117 but resistant to any autologous HIV-1 neutralizing serum activity. In all uninfected subjects serum samples were tested against Q769.d22 and ID 50 values were derived by using a 5-parameter curve fitting, considering accurate within the pre-established limits (threefold variation with a 20% error rate). The serum concentration of active 3BNC117 was calculated by taking into account the sera ID 50 titres multiplied by the known IC 50 of 3BNC117 for Q769.d22. In HIV-1-infected subjects pre-infusion samples were first tested against a panel of 3BNC117-sensitive HIV-1 strains that included Q769.d22 (Clade A1, Tier 2), YU2.DG (Clade B, Tier 2), Q259.d2.17 (Clade C, Tier 1B), Q842.d12 (Clade A1, Tier 2), ZM135M.PL10a (Clade C, Tier 2), and TRO.11 (Clade B, Tier 2). A single strain per subject was selected that showed no or only minimal background activity and 3BNC117 serum levels were determined in the same way as described for Q769.d22. Pharmacokinetic analysis. Blood samples were collected immediately before, at the end, 0.5, 3, 6, 9, 12 and 24 h after completion of the 3BNC117 infusion, and on days 2, 4, 7, 14, 21, 28, 42 and 56. 3BNC117 serum levels were obtained from ELISA (Celldex Therapeutics) and TZM.bl neutralization assay, and PK-parameters were estimated by performing a non-compartmental analysis (NCA) using WinNonlin 6.3. Neutralization assay. Serum samples, viral supernatants, and control antibodies were tested against HIV-1 envelope pseudoviruses as previously described 33, 34 . Virus cultures. Autologous virus was retrieved from HIV-1 infected individuals as previously described 35 . Briefly, healthy donor peripheral blood mononuclear cells (PBMCs) were obtained by leukapheresis from a single donor. Cells were cultured at a concentration of 5 3 10 6 ml 21 in Iscove's modified Dulbecco's medium (IMDM; Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone, Thermo Scientific), 1% penicillin/streptomycin (Gibco), and 1 mg ml 21 phytohaemagglutinin (Life Technologies) at 37 uC and 5% CO 2 . After 2-3 days, 5 3 10 6 cells were transferred into IMDM supplemented with 10% FBS, 1% penicillin/streptomycin, 5 mg ml 21 polybrene (Sigma), and 10 U ml 21 of IL-2, and co-incubated with 2-3 3 10 6 PBMCs from the study participants obtained before and 28 days or later after 3BNC117 infusion (Extended Data Table 3 ). Media was replaced on a weekly basis and culture supernatants quantified using the Alliance HIV-1 p24 Antigen ELISA kit (PerkinElmer) according to the manufacturer's instructions. Tissue culture infectious dose for 50% of cells (TCID 50 ) values were determined for all HIV-1 containing supernatants 33,34 and then tested for sensitivity against 3BNC117 in a TZM.bl neutralization assay. Outgrowth of autologous virus isolates from subjects with low level viraemia was performed as previously described 36 . Briefly, 2-5 million CD4
1 T cells were cultured in the presence of 10 million irradiated healthy donor PBMCs and 3 million healthy donor PHA stimulated CD8 1 depleted lymphoblasts. Lymphoblasts were replenished weekly by adding 3 million healthy donor PHA stimulated CD8 1 depleted lymphoblasts. Blood samples and leukopheresis were collected under separate IRB-approved protocols and after study participants provided informed consent. Sequence analysis. HIV-1 RNA was extracted from plasma samples using the Qiagen MinElute Virus Spin kit (Qiagen) followed by first strand cDNA synthesis using SuperScript III reverse transcriptase (Invitrogen Life Technologies) and the antisense primer env3out 59-TTGCTACTTGTGATTGCTCCATGT-39 37 or 59-GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-39 6 . gp160 env was amplified using envB5out 59-TAGAGCCCTGGAAGCATCCAGGAAG-39 and envB3out 59-TTGCTACTTGTGATTGCTCCATGT-39 in the first round and second round nested primers envB5in 59-CACCTTAGGCATCTCCTATG-GCAGGAAGAAG-39 and envB3in 59-GTCTCGAGATACTGCTCCCACCC-39. First round PCR was performed using a High Fidelity Platinum Taq (Invitrogen) at 94 uC, 2 min; (94 uC, 15 s; 55 uC 30 s; 68 uC, 4 min) 3 35; 68 uC, 15 min. Second round PCR was performed with 2 ml of 1. PCR product as template and Phusion Hot Start Polymerase at 98 uC, 30 s; (98 uC, 8 s; 55 uC, 20 s; 72 uC, 1 min) 3 35; 72 uC, 6 min. gp120 env was amplified using first round primers and conditions as described, but second round was performed by using second round nested primers 59-TAGAAAGAGCAGAAGACAGTGGCAATGA-39 and 59-TCATCAATGGTGGTGATGATGATGTTTTTCTCTCTGCACCACTCTTCT-39. Second round PCR was performed with 1 ml of 1. PCR product as template and High Fidelity Platinum Taq (Invitrogen) at cycling conditions, 94 uC, 2 min; (94 uC, 15 s; 58 uC, 35 s; 68 uC, 2 min and 30 s) 3 35; 68 uC, 10 min. Following the second-round PCR amplification, 0.5 ml Taq polymerase was added to each 50 ml reaction and an additional 72 uC extension for 15 min was performed to add 39dA overhangs for cloning inserts into pCR4-TOPO. PCR amplicons were gelpurified and ligated into pCR4-TOPO (Invitrogen) or pcDNA3.1 (Invitrogen), followed by transfection into MAX Efficiency Stbl2 Competent Cells (Life Technologies). Individual colonies were analysed for insert length by PCR, and successfully cloned envelopes sequenced by a set of env specific primers. Sequence alignments and mutation analysis of gp120 and gp160 was performed by using Geneious Pro software, version 5.6.7 (Biomatters Ltd), and residues were numbered according to HXBc2. Phylogenetic trees were generated using the PhyML tool at the Los Alamos HIV website 38 , and sequence analysis was performed using Antibody database by Anthony West 39 . Logograms were generated using the Weblogo 3.0 tool 40 . Selected sequences were used to generate pseudoviruses and tested for 3BNC117 sensitivity in a TZM.bl assay 37 . Statistical analyses. The sample size to detect .1 log 10 decline in viraemia with 80% power at 5% of significance was determined to be 5 HIV-1-infected individuals, not on ART, infected with 3BNC117-sensitive viruses assuming that the standard deviation would be similar to 3BNC117 effects in hu-mice 9 . Adverse events were summarized by the number of subjects who experienced the event, by severity grade and by relationship to 3BNC117 according to the DAIDS AE Grading Table ( HIV-1-infected groups) or the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (uninfected groups). PK-parameters were estimated by performing a non-compartmental analysis (NCA) using WinNonlin 6.3. CD4
1 and CD8 1 T-cell counts before and after 3BNC117 were analysed by one-way ANOVA. To assess the changes in HIV-1 viral loads, we used a mixed-effect linear model where dose and time were fixed effects and random intercepts for each participant. These models take full advantage of the repeated measure structure of the data while estimating parameters for each dose simultaneously, hence improving the power of small study groups. The final model was fitted assuming an AR(1) correlation structure over time, which was the best in terms of AIC/BIC criteria. The significance of the effect of 3BNC117 on viral load, defined as change between each time point and day 0, was assessed using least-squares means within each dose group (Extended Data Table 2b ). Sensitivity analysis was also carried out with variations of these models and the same conclusions were achieved. Pearson and nonparametric Spearman coefficients were calculated to assess the correlation between maximum drop in viraemia after 3BNC117 infusion and baseline HIV-1 viral load or baseline sensitivity of autologous viruses to 3BNC117. and CD8 1 T cells for the same subjects and time points. Mean and standard deviation are indicated in red and black, respectively. No significant differences between pre-infusion and post infusion levels were detected by using one-way ANOVA. Antibody levels were measured by a sandwich ELISA using an anti-3BNC117 specific antibody (green) or by measuring the 3BNC117 serum activity in a TZM.bl neutralization assay (blue). Extended Data 
30 mg/kg 10 mg/kg 3 mg/kg 1 mg/kg a, HIV-1 RNA levels. Subjects 2B2 and 2C2 were on ART. Subject 2D3 started ART after day 42. Screen was performed between day 249 and day 214. Viraemia measurements at "Pre" were performed between day 242 and day 22. b, Viral decay mixed-effect linear model. Estimation of PK parameters retrieved from study participants (ID) up to 8 weeks post 3BNC117 infusion. 3BNC117 was administered at 1, 3, 10, and 30 mg kg 21 in uninfected (Negative) and HIV-1-infected (Positive) individuals. 3BNC117 serum concentrations were determined by ELISA or TZM.bl assay (see Methods). PK-parameters were obtained by performing a non-compartmental analysis (NCA) using WinNonlin 6.3. T1/2 was estimated using values between Lambda upper/lower. n.d., PK parameters were not determined because of insufficient data or an extrapolated AUC_inf that exceeded 25%. Values in red indicate extrapolated AUC_inf .10%. *Days post infusion of 3BNC117.
Extended Data
Extended Data (1) Estimation of half-lives; SD, standard deviation.
